437 related articles for article (PubMed ID: 19696442)
1. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study.
Ferrer R; Artigas A; Suarez D; Palencia E; Levy MM; Arenzana A; Pérez XL; Sirvent JM;
Am J Respir Crit Care Med; 2009 Nov; 180(9):861-6. PubMed ID: 19696442
[TBL] [Abstract][Full Text] [Related]
2. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.
Dellinger RP; Levy MM; Carlet JM; Bion J; Parker MM; Jaeschke R; Reinhart K; Angus DC; Brun-Buisson C; Beale R; Calandra T; Dhainaut JF; Gerlach H; Harvey M; Marini JJ; Marshall J; Ranieri M; Ramsay G; Sevransky J; Thompson BT; Townsend S; Vender JS; Zimmerman JL; Vincent JL; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
Crit Care Med; 2008 Jan; 36(1):296-327. PubMed ID: 18158437
[TBL] [Abstract][Full Text] [Related]
3. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
Micek ST; Isakow W; Shannon W; Kollef MH
Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
[TBL] [Abstract][Full Text] [Related]
4. Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department.
Nguyen HB; Corbett SW; Menes K; Cho T; Daugharthy J; Klein W; Wittlake WA
Acad Emerg Med; 2006 Jan; 13(1):109-13. PubMed ID: 16365336
[TBL] [Abstract][Full Text] [Related]
5. Assessing the effect of the Surviving Sepsis Campaign treatment guidelines on clinical outcomes in a community hospital.
Patel GW; Roderman N; Gehring H; Saad J; Bartek W
Ann Pharmacother; 2010 Nov; 44(11):1733-8. PubMed ID: 20978215
[TBL] [Abstract][Full Text] [Related]
6. Resuscitation bundle compliance in severe sepsis and septic shock: improves survival, is better late than never.
Coba V; Whitmill M; Mooney R; Horst HM; Brandt MM; Digiovine B; Mlynarek M; McLellan B; Boleski G; Yang J; Conway W; Jordan J;
J Intensive Care Med; 2011; 26(5):304-13. PubMed ID: 21220270
[TBL] [Abstract][Full Text] [Related]
7. Activated protein C and septic shock: a propensity-matched cohort study*.
Rimmer E; Kumar A; Doucette S; Marshall J; Dial S; Gurka D; Dellinger RP; Sharma S; Penner C; Kramer A; Wood K; Ronald J; Kumar A; Turgeon AF; Houston DS; Zarychanski R;
Crit Care Med; 2012 Nov; 40(11):2974-81. PubMed ID: 22932397
[TBL] [Abstract][Full Text] [Related]
8. Time- and fluid-sensitive resuscitation for hemodynamic support of children in septic shock: barriers to the implementation of the American College of Critical Care Medicine/Pediatric Advanced Life Support Guidelines in a pediatric intensive care unit in a developing world.
Oliveira CF; Nogueira de Sá FR; Oliveira DS; Gottschald AF; Moura JD; Shibata AR; Troster EJ; Vaz FA; Carcillo JA
Pediatr Emerg Care; 2008 Dec; 24(12):810-5. PubMed ID: 19050666
[TBL] [Abstract][Full Text] [Related]
9. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
[TBL] [Abstract][Full Text] [Related]
10. Masseter tissue oxygen saturation predicts normal central venous oxygen saturation during early goal-directed therapy and predicts mortality in patients with severe sepsis.
Colin G; Nardi O; Polito A; Aboab J; Maxime V; Clair B; Friedman D; Orlikowski D; Sharshar T; Annane D
Crit Care Med; 2012 Feb; 40(2):435-40. PubMed ID: 22020233
[TBL] [Abstract][Full Text] [Related]
11. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
[TBL] [Abstract][Full Text] [Related]
12. Effects of fluid resuscitation with synthetic colloids or crystalloids alone on shock reversal, fluid balance, and patient outcomes in patients with severe sepsis: a prospective sequential analysis.
Bayer O; Reinhart K; Kohl M; Kabisch B; Marshall J; Sakr Y; Bauer M; Hartog C; Schwarzkopf D; Riedemann N
Crit Care Med; 2012 Sep; 40(9):2543-51. PubMed ID: 22903091
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of treatments for severe sepsis: data from the bundle implementation programs.
Ferrer R; Artigas A
Minerva Anestesiol; 2011 Mar; 77(3):360-5. PubMed ID: 21441890
[TBL] [Abstract][Full Text] [Related]
14. The role of bundles in sepsis care.
Hurtado FJ; Nin N
Crit Care Clin; 2006 Jul; 22(3):521-9, x. PubMed ID: 16893737
[TBL] [Abstract][Full Text] [Related]
15. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.
Dellinger RP; Levy MM; Carlet JM; Bion J; Parker MM; Jaeschke R; Reinhart K; Angus DC; Brun-Buisson C; Beale R; Calandra T; Dhainaut JF; Gerlach H; Harvey M; Marini JJ; Marshall J; Ranieri M; Ramsay G; Sevransky J; Thompson BT; Townsend S; Vender JS; Zimmerman JL; Vincent JL
Intensive Care Med; 2008 Jan; 34(1):17-60. PubMed ID: 18058085
[TBL] [Abstract][Full Text] [Related]
16. ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation.
Laterre PF; Abraham E; Janes JM; Trzaskoma BL; Correll NL; Booth FV
Crit Care Med; 2007 Jun; 35(6):1457-63. PubMed ID: 17452935
[TBL] [Abstract][Full Text] [Related]
17. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.
Laterre PF; Levy H; Clermont G; Ball DE; Garg R; Nelson DR; Dhainaut JF; Angus DC
Crit Care Med; 2004 Nov; 32(11):2207-18. PubMed ID: 15640632
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of the effect of fluid resuscitation as guided either by lactate clearance rate or by central venous oxygen saturation in patients with sepsis].
Yu B; Tian HY; Hu ZJ; Zhao C; Liu LX; Zhang Y; Zhu GJ; Wang LT; Wu XH; Li J
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Oct; 25(10):578-83. PubMed ID: 24119693
[TBL] [Abstract][Full Text] [Related]
19. [Recommendations for management of severe sepsis and septic shock. Surviving sepsis campaign].
Martin C; Garnier F; Vallet B
Ann Fr Anesth Reanim; 2005 Apr; 24(4):440-3. PubMed ID: 15826800
[No Abstract] [Full Text] [Related]
20. A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study.
Vincent JL; Laterre PF; Decruyenaere J; Spapen H; Raemaekers J; Damas F; Rogiers P; Sartral M; Haentjens T; Nelson D; Janes J
Acta Clin Belg; 2008; 63(1):25-30. PubMed ID: 18386762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
